- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.06. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.06. | Reviva Dives on Stock Offering | 2 | Baystreet.ca | ||
| 26.06. | Reviva Pharmaceuticals holdings announces pricing of $10M public offering | 2 | Seeking Alpha | ||
| 26.06. | Reviva preist öffentliches Angebot von 10 Millionen US-Dollar zu 0,50 US-Dollar pro Aktie | 2 | Investing.com Deutsch | ||
| 26.06. | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 25.06. | Reviva Pharmaceuticals-Aktie fällt nach Ankündigung eines öffentlichen Angebots | 11 | Investing.com Deutsch | ||
| 25.06. | Reviva Pharmaceuticals announces public offering of common stock | 1 | Investing.com | ||
| 25.06. | Reviva Pharmaceuticals stock falls after announcing public offering | 1 | Investing.com | ||
| 25.06. | Reviva Pharmaceuticals announces public offering; shares down nearly 15% | 1 | Seeking Alpha | ||
| 25.06. | Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 06.06. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.06. | Reviva reports positive year-long schizophrenia drug study | 3 | Investing.com | ||
| 02.06. | Reviva Pharmaceuticals: Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia | 264 | GlobeNewswire (Europe) | - Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms - - Generally well-tolerated with low rates of adverse events and discontinuation... ► Artikel lesen | |
| 30.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.05. | Benchmark hält 14 US-Dollar Kursziel für Reviva Pharmaceuticals-Aktie aufrecht | 3 | Investing.com Deutsch | ||
| 20.05. | Reviva stock target cut to $3 on cash concerns, retains Buy rating | 5 | Investing.com | ||
| 15.05. | Reviva Pharmaceuticals GAAP EPS of -$0.13 | 8 | Seeking Alpha | ||
| 15.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights | 164 | GlobeNewswire (Europe) | - 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment - - Full data set from RECOVER OLE... ► Artikel lesen | |
| 09.04. | Reviva Pharmaceuticals target cut to $14 by Benchmark | 2 | Investing.com | ||
| 03.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 28,475 | +2,41 % | DAX höher: Netflix, Tesla, Munich Re, Bayer, Siemens, Commerzbank, BASF, VW, Porsche im Fokus | Der DAX hat am Mittwoch den fünften Tag in Folge mit Verlusten abgeschlossen. Aus dem Handel ging er mit einem Minus von 0,2 Prozent bei 24.009,38 Zählern. Der Start in den Donnerstag dürfte aber weitaus... ► Artikel lesen | |
| PFIZER | 21,615 | +0,37 % | Bristol Myers Squibb, Pfizer Announce Direct-to-patient Option For Eliquis | NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) and Pfizer (PFE) Thursday announced a direct-to-patient option for purchasing their blood thinner medicine, Eliquis through the partnership's... ► Artikel lesen | |
| ROCHE | 275,40 | -1,11 % | Roche: Doppelter Rückschlag | Doppelter Dämpfer für den Pharma-Riesen Roche. Für das Krebsmittel Columvi hat die US-Zulassungsbehörde FDA erneut einen negativen Entscheid gefällt. Darüber hinaus muss das Schweizer Unternehmen einen... ► Artikel lesen | |
| VIATRIS | 7,930 | -0,43 % | Why Is Viatris Stock Falling In Pre-market? | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% ophthalmic ointment... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 4,988 | +2,09 % | Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold? | ||
| CASSAVA SCIENCES | 2,283 | -0,48 % | Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development | AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 7,660 | -0,13 % | Edison Group: Edison Issues Report on Newron Pharmaceuticals (NWRN) | London, United Kingdom--(Newsfile Corp. - July 9, 2025) - Edison issues report on Newron Pharmaceuticals (SIX: NWRN).Newron Pharmaceuticals is making significant headway in progressing its drug candidate... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 1,787 | -7,93 % | ORAMED PHARMACEUTICALS INC. - 8-K, Current Report | ||
| ACHIEVE LIFE SCIENCES | 2,350 | +0,86 % | Achieve Life Sciences: Trading-Chance bei Anti-Raucher-Aktie | SD-Leser kennen die Aktie von Achieve Life Sciences von früheren Höhenflügen noch gut. Immer wieder konnten wir uns gezielt Trading-Dynamiken zunutze machen und teils dreistellige Gewinne einfahren.... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,504 | -3,82 % | Leerink Partners bekräftigt Outperform-Rating für Aurinia-Aktie nach Studiendaten | ||
| KAZIA THERAPEUTICS | 10,300 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase ... | SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial... ► Artikel lesen | |
| LIPOCINE | 3,370 | 0,00 % | Lipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression | Phase 3 Top Line Results Expected Q2 2026
SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,100 | 0,00 % | Allergy Therapeutics shares slump as expects to post revenue decline | ||
| LYRA THERAPEUTICS | 8,390 | +2,32 % | Lyra Therapeutics registers shares for resale from warrant exercises | ||
| SUNSHINE BIOPHARMA | 1,580 | 0,00 % | Sunshine Biopharma Inc.: Sunshine Biopharma Launches NIOPEG Into $10 Billion Biologics Market | FORT LAUDERDALE, FL / ACCESS Newswire / July 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen |
REVIVA PHARMACEUTICALS HOLDINGS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,421 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.